The Direxion Daily Healthcare Bull 3X ETF (CURE) has declined in early 2026 due to investors taking profits after strong gains in late 2025. Despite this short-term correction, analysts expect significant growth for CURE's top holdings over the next year. The ETF's high leverage and expense ratio make it more suitable for trading rather than long-term holding, but long-term investors may benefit from trends like an aging U.S. population and AI advancements in drug research. This dip may also offer an opportunity to shift investments from the less leveraged XLV ETF to CURE for potentially higher returns.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
XRP surged about 4% to $1.11 following a broader crypto market rebound triggered by softer U.S. inflation data. Technical signals suggest a bullish inverse head and shoulders pattern, with potential for a 20% price increase if XRP breaks the $1.12–$1...
Revolut has received preliminary approval from Dubai's Virtual Assets Regulatory Authority to offer cryptocurrency services in the UAE, including broker-dealer, asset management, and exchange functions. This approval allows UAE customers to trade and...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
